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patients 114 lesions, 38.5±12.8mm, 43.9±19.5mm), EES (88 patients 94 lesions,
34.2±13.8mm, 40.1±14.8mm) and ZES-R (80 patients 88 lesions, 37.1±13.9mm,
42.3±17.3mm) respectively. We conducted follow-up coronary angiogram in all
patients after successful implantation of SES, PES, EES and ZES-R (9, 12, 18, 24, 36
months respectively).
Results: See table for clinical results.
Conclusion: There is a different timing of late catch up phenomenon (late lumen loss)
of SES, PES, EES and ZES-R (SES: 12-18 months, PES: 9-12 months, EES: 12-18
months and ZES-R: 12-24 months) after successful implantation of SES, PES, EES
and ZES-R in patients with chronic total occlusion. Patients treated with SES, EES
and ZES-R showed lesser loss of minimum lumen diameter compared with PES.
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Elevated Pre-procedural High-sensitive CRP Levels are Associated with Uneven
Vessel Healing after Paclitaxel-eluting Stents Implantation in Patients with
Stable Angina
Hiromasa Otake, Junya Shite, Toshiro Shinke, Ken-ichi Hirata
Kobe University Graduate School of Medicine, Kobe, Japan
Background: Pre-procedural inflammation may deteriorate uniform vessel healing
after paclitaxel-eluting stents (PES) deployment.
Methods: Fifty-four lesions treated with PES were evaluated with 6-month follow-up
OCT. All lesions were grouped into tertiles according to pre-procedural hs-CRP level:
tertile 1 (<0.05 mg/dl), tertile 2 (0.05-0.16 mg/dl), tertile 3 (>0.16mg/dl). To assess
unevenness of neointima thickness (NIT), neointimal unevenness score (NUS: max
NIT in the cross section (CS) / average NIT of the same CS) was calculated and
averaged for each stent. Longitudinal and circumferential variability of NIT was
evaluated in 3-dimensions by computing mean NIT within 360 equally-spaced radial
sectors for every 1mm CS. To assess longitudinal variability, NIT within the same
sector was corrected from different CS. Longitudinal standard deviation (SD) was
calculated for each sector. The longitudinal SD from each sector was averaged across
the 360 different sectors. For assessing circumferential variability, SD of NIT within
the same CS was calculated and averaged along the long axis direction. (Figure)
Results: Despite similar NIT, tertile 3 group showed significantly a greater NUS with
a greater %uncovered struts than others. There was a significant positive correlation
between pre-procedural hs-CRP and NUS (R=0.67, P<0.001). Longitudinal and
circumferential variability increased along with increased hs-CRP level. The incidence
of thrombus was highest in the tertile 3 group.
Conclusion: Pre-procedural inflammation may play a key role in delayed arterial
healing by deteriorating uniform vessel healing after PES implantation.
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Background: Patients treated for bifurcation lesions are at high risk for clinical
restenosis and stent thrombosis. The e-HEALING registry was designed to capture
clinical data on the use of the Genous™ Bio-engineered R stent™, an Endothelial
Progenitor Cell capturing stent (ECS), in routine clinical practice. In our current
analysis, we investigated the 12-month clinical outcomes in patients treated with an
ECS for a bifurcation lesion.
Methods: The worldwide, prospective, non-randomized e-HEALING registry aimed
to enrol 5000 patients treated for coronary artery disease with ≥1 ECS between October
2005 and October 2007. Clinical follow-up was at 1, 6 and 12 months. The primary
end point was Target Vessel Failure (TVF), defined as cardiac death, myocardial
infarction, or target vessel revascularization (TVR) at 12 months.
Results: A total of 573 patients (11.6%) were treated for at least one bifurcation lesion
and assessed in the current analysis. Baseline characteristics showed a median age of
65 years, 21% diabetics and 36% had unstable angina. A total of 63% of the bifurcation
lesions was located in the LAD and mean stent length was 20.7 mm. At 12-months,
TVF was 12.7% and TVR was 7.5%. Definite or probable stent thrombosis occurred
in 1.7%.
Conclusion: In the e-HEALING registry, coronary bifurcation stenting with an ECS
results in favourable clinical outcomes and low incidences of repeat revascularization
and stent thrombosis.
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Impact of Stent Fracture on Stent Thrombosis After Drug-eluting Stent and
Bare-metal Stent Implantations
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Background: It has been reported that stent fracture after drug-eluting stent (DES)
implantation was related to stent thrombosis. However, there is no data available to
evaluate the association between stent fracture and stent thrombosis considering the
stent type. We investigated the relationship between stent fracture and stent thrombosis,
classified by the occurrence time after DES and bare-metal stent (BMS) implantations:
subacute stent thrombosis (SAT); late stent thrombosis (LST); and very late stent
thrombosis (VLST).
Methods: From January 2001 to March 2011, 8802 lesions (5683 patients) were treated
with BMS and 12079 lesions (8365 patients) were treated with DES. In these patients,
we reviewed the lesions with SAT, LST, and VLST. Stent fracture was defined as
apparent strut separation found by coronary angiography. Stent thrombosis was defined
according to the Academic Research Consortium definition.
Results: SAT occurred in 28 lesions (25 patients) after DES implantation and 40 lesions
(34 patients) after BMS implantation. LST occurred in 12 lesions (12 patients) after
DES implantation and 22 lesions (22 patients) after BMS implantation. VLST occurred
in 27 lesions (25 patients) after DES implantation and 17 lesions (17 patients) after
BMS implantation. The figure shows that stent fracture in stent thrombosis was
significantly more often observed after DES implantation than BMS implantation,
especially in LST and VLST. No stent fracture was observed in stent thrombosis after
BMS implantation.
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Conclusion: After BMS implantation, stent fracture could have no effect on stent
thrombosis. However, stent fracture after DES implantation could have impact on stent
thrombosis as time passes.
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Background: Implantation of long and multiple overlapping DES in diffusely diseased
vessels, is frequently performed in routine clinical practice. Despite their widespread
use, concerns have been raised regarding DES safety and efficacy for treatment of
diffuse disease or long lesions requiring multiple stent implantation. In this registry,
we assessed the performance of the second generation Resolute Zotarolimus-eluting
stent (ZES) in this specific subgroup of patients.
Methods: From August 2008, 314 patients treated in 10 Italian Centers with >31.5mm
Resolute stent were prospectively followed in the context of the Clinical-Service
program. Comparison with patients receiving <31.5 mm of stents was also
performed.Patients were divided in two groups according to the length of the stent
implanted: group 1[(n=731)Short Stent, SS]: stented segment length≤ 31.5mm; group
2 [(n= 314) Long Stent, LS]: stented segment length >31.5mm. We compare the
incidence of MACE (cardiac death, re-myocardial infarction, TLR ), stent thrombosis
(ST) and target vessel revascularization (TVR) in the two groups.
Results: 314 patients(575 lesions) with a total ZES length >31.5 mm was collected in
the LS group (79% male, 66±10 years, 33% diabetic). The mean follow up was
244±160 days.SS group was composed of 731 patients (77% male, 65±11 years, 30%
diabetic) followed for a mean time of 316±295 days.There was no significant difference
in the overall incidence of MACE among the two groups (5.6% in LS versus 5.7% in
SS, p=ns).The incidence of cardiac death (1.8% vs. 2.5%), acute myocardial infarction
(2.8% vs. 2.6%), TLR (2.4% vs. 2.6%) and TVR (5.5% vs. 6.9%) was similar in the
long and short stent group (p=ns), respectively. No difference was found in ST between
the LS vs. SS groups (definite: 0.6% vs. 0.3%, p=0.37; probable: 0% vs. 1.4%,
p=0.27;early: 0.6% vs. 0.3%, p=ns; late: 0.6% vs. 2% p=ns). Dual antiplatelet therapy
discontinuation before 12 months was similar in the two groups (LS=1.6%, SS=2.9%,
p=ns).
Conclusion: In this multicentre prospective study, implantation of the Resolute ZES
for the treatment of diffuse and long coronary artery disease appears effective and safe.
Multiple or long Resolute stent implantation was associated with an acceptable MACE
rate at mid-to-long term follow-up without a significant increase in the risk of ST.
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Background: Since the approval of Drug-Eluting Stents (DES) in Europe in 2002,
DES have been quickly entering into daily clinical practice even in indications without
data from randomised controlled clinical trials (off-label use). At the European and
World Congress of Cardiology in Barcelona 2006, alarming data were presented on a
worse long-term prognosis following DES implantation compared with BMS. This
resulted in a higher cautiousness for its use with a decrease of DES implantations in
clinical practice.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were
enrolled into the PCI-Registry of the Euro Heart Survey Programme to document
patient characteristics, PCI details and hospital complications in different PCI
indications. We examined the development of DES use over time by splitting the
enrolment period into 6- months periods (Jan-Jun and Jul-Dec) for the years 2005 to
2008 to identify a possible collapse in DES use and its further development following
September 2006.
Results: A total of 22,917 patients underwent elective PCI, 24,090 PCI for ACS. From
the very beginning of the documentation period the use of DES was high with about
60% in elective PCI and about 50% in PCI for ACS. After the presentation of the
alarming data on long-term outcome after DES during the ESC Congress in 2006, the
use of DES significantly decreased to 43% in elective PCI (p<0.01) and to 33% in PCI
for ACS (p<0.01) and remained low since then.
Conclusion: In consecutive patients undergoing elective PCI as well as PCI for ACS
in Europe, the use of DES collapsed after the presentation of alarming data of a worse
long- term prognosis following DES implantation during the ESC-Congress 2006.
Despite re-assuring data on the safety of DES, the use of DES did not recover in clinical
practice in Europe.
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Background: Efficacy and safety data following sirolimus-eluting stent (SES) PCI in
unselected patients at very long-term follow-up (>5 years) are still limited.
Methods: all consecutive patients with significant coronary artery stenosis treated with
PCI and only SES implantation between December 2001 and February 2003 were
analyzed in order to assess the survival-free from major adverse cardiovascular events
(MACE) defined as a composite of death, myocardial infarction (MI) and target vessel
revascularization (TVR) and survival-free from target lesion failure (TLF) defined as
a composite of cardiac death, target vessel-MI (TV-MI) and target lesion
revascularization (TLR).
Results: 447consecutive patients (954 lesions) treated with SES implantation were
treated in the study period. Mean age was 61.9±10.4 years, 399 (89.3%) patients were
male, 99 (22.1%) had diabetes mellitus, and 356 (79.6%) had multi-vessel disease. Of
the 954 lesions treated, 771 (80.8%) were ACC/AHA type B2/C including ostial
(19.5%), bifurcation (18.6%), restenotic (16.2%), chronic total occlusions (9.9%) and
left main (9.1%) lesions. Mean number of stents implanted per patients was 2.03 ±
1.04. Median dual antiplatetlet therapy (DAT) duration was 253 (IQR 162-1197) days.
Clinical follow-up was available at 8 years in 403 eligible patients (90.2%). The
cumulative incidence of events at 8 years was: death 15.7% (65 patients), cardiac death
8.3% (34 patients); MI 7.9% (32 patients), TV-MI 6.2% (25 patients) and TVR 41.2%
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